Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
PS Thomas
Observed name:
P Thomas
Institution:
Genentech
Observed institutions:
Northwestern University,
National Institutes of Health,
Mayo Clinic,
The University of Texas MD Anderson Cancer Center,
University of Alabama,
Baylor College of Medicine,
Genentech,
GlaxoSmithKline (United States),
Dana-Farber Cancer Institute,
National Cancer Institute
show all 10
OpenAlex ID:
A5034829075
A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)
2021
·
P Schmid
, PL Bedard
, et al.
·
Senologie - Zeitschrift für Mammadiagnostik und -therapie
·
1
Abstract OT2-09-02: A phase I dose escalation study of topical bexarotene in women at high risk for breast cancer
2019
·
PS Thomas
, AB Patel
, et al.
·
Cancer Research
·
1
Abstract PD3-07: A phase II pre-surgical trial of lapatinib for the treatment of women with HER2 positive or EGFR positive ductal carcinoma in situ
2019
·
PS Thomas
, A Contreras
, et al.
·
Cancer Research
Aggressive Lymphoma. Initial Management of Early Stage
2006
·
PS Thomas
·
Medical Entomology and Zoology
Show more works
View as search
Works count:
4
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type
